Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quali
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally
The Phase II/III INDUCE-3 trial was terminated early after the ICOS agonist feladilimab plus pembrolizumab failed to show superiority over pembrolizumab monotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma
This review analyzes the impact of individualized prognostic counseling on decisional conflict and regret in patients with head and neck squamous cell carcinoma, highlighting the efficacy of online prognostic tools in fostering shared decis
A multicenter study demonstrates that deep transfer learning (DTL) algorithms using preimplant MRI can predict spoken language development in children with cochlear implants with over 92% accuracy, significantly outperforming traditional ma
A comprehensive meta-analysis demonstrates that patients with papillary thyroid microcarcinoma managed via active surveillance experience significantly better health-related quality of life and fewer treatment-related symptoms than those un
A landmark propensity-matched study from Memorial Sloan Kettering Cancer Center demonstrates that thyroid lobectomy with neck dissection provides similar survival and recurrence outcomes to total thyroidectomy plus radioactive iodine for sp
A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate
A prospective cohort study demonstrates that a structured shared decision-making (SOP) model significantly increases the utilization of multidisciplinary palliative care services for patients with stage IV oral cavity cancer, bridging the g
A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a
A pilot trial finds biofeedback and respiratory retraining equally effective for inducible laryngeal obstruction, offering clinicians flexible, patient-tailored options.
A large prospective study links smell disturbances to at least 139 conditions. Olfactory loss can be an early sign of neurological, ENT, metabolic, or systemic disease — and a practical, underused screening tool clinicians can adopt.
Secondary analysis of three RTOG/NRG trials shows radiotherapy interruptions are associated with higher locoregional failure and worse overall survival in head and neck cancer, with larger absolute harms in p16‑negative and high‑stage disea
This case series reviews clinical features, genetic variants, visual outcomes, and psychosocial impact in 28 patients with USH1C-associated Usher syndrome, highlighting slow retinal degeneration and significant social burden.
In a large single‑institution cohort of oropharyngeal squamous cell carcinoma, proton therapy was associated with a higher 3‑year rate of osteoradionecrosis than IMRT (6.4% vs 2.7%), though severe ORN remained uncommon.
A randomized, double-blind placebo-controlled proof-of-concept trial of engasertib (AKT inhibitor) in hereditary hemorrhagic telangiectasia showed modest reductions in epistaxis frequency and duration versus placebo and a tolerable safety p
In a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversible
A nationally representative 2022 study found hearing loss in 54.6% of Hispanic US adults 65+; only 8.3% of those with hearing loss reported using hearing aids, underscoring major access gaps.
A large single-center cohort (n=7,622) shows 12.6% of head and neck cancer patients develop severe (≥RTOG grade 3) radiation-related late toxicities; modifiable factors and specialized multidisciplinary late-effects care may reduce risk and
Longitudinal data from 403 head and neck cancer survivors show that while information and health-system needs decline between years 2 and 5, one-third report at least one moderate-to-high unmet supportive care need at year 5—notably fatigue
Open language-specific specialty feeds and department pages.